EXAS EXACT SCIENCES CORP

Nasdaq exactsciences.com


$ 100.88 $ 0.23 (0.23 %)    

Friday, 21-Nov-2025 15:54:56 EST
QQQ $ 590.41 $ 4.40 (0.75 %)
DIA $ 462.65 $ 5.05 (1.1 %)
SPY $ 658.95 $ 6.50 (1 %)
TLT $ 89.48 $ 0.27 (0.3 %)
GLD $ 373.72 $ -0.58 (-0.15 %)
$ 100.9
$ 100.93
$ 100.81 x 2,580
$ 100.83 x 1,126
$ 100.75 - $ 101.04
$ 38.81 - $ 101.87
19,080,350
na
19.12B
$ 1.29
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-03-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-01-2025 03-31-2025 10-Q
4 02-19-2025 12-31-2024 10-K
5 11-05-2024 09-30-2024 10-Q
6 07-31-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 02-21-2024 12-31-2023 10-K
9 11-01-2023 09-30-2023 10-Q
10 08-01-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 02-21-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-02-2022 06-30-2022 10-Q
15 04-26-2022 03-31-2022 10-Q
16 02-22-2022 12-31-2021 10-K
17 11-02-2021 09-30-2021 10-Q
18 07-28-2021 06-30-2021 10-Q
19 05-04-2021 03-31-2021 10-Q
20 02-16-2021 12-31-2020 10-K
21 10-27-2020 09-30-2020 10-Q
22 07-31-2020 06-30-2020 10-Q
23 05-06-2020 03-31-2020 10-Q
24 02-21-2020 12-31-2019 10-K
25 10-30-2019 09-30-2019 10-Q
26 07-30-2019 06-30-2019 10-Q
27 04-30-2019 03-31-2019 10-Q
28 02-21-2019 12-31-2018 10-K
29 10-30-2018 09-30-2018 10-Q
30 08-01-2018 06-30-2018 10-Q
31 04-26-2018 03-31-2018 10-Q
32 02-22-2018 12-31-2017 10-K
33 10-30-2017 09-30-2017 10-Q
34 07-25-2017 06-30-2017 10-Q
35 04-27-2017 03-31-2017 10-Q
36 02-21-2017 12-31-2016 10-K
37 10-26-2016 09-30-2016 10-Q
38 07-26-2016 06-30-2016 10-Q
39 05-03-2016 03-31-2016 10-Q
40 02-24-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 deal-dispatch-abbott-tpg-and-lonza-make-major-moves-mm-custard-and-new-fortress-energy-struggle

Abbott buys Exact Sciences for $21B; TPG invests $1B in Tata Consultancy; and New Fortress Energy is on bankruptcy watch.

 wells-fargo-downgrades-exact-sciences-to-equal-weight-raises-price-target-to-105

Wells Fargo analyst Brandon Couillard downgrades Exact Sciences (NASDAQ:EXAS) from Overweight to Equal-Weight and raises the...

 william-blair-downgrades-exact-sciences-to-market-perform

William Blair analyst Andrew Brackmann downgrades Exact Sciences (NASDAQ:EXAS) from Outperform to Market Perform.

 guggenheim-downgrades-exact-sciences-to-neutral

Guggenheim analyst Subbu Nambi downgrades Exact Sciences (NASDAQ:EXAS) from Buy to Neutral.

 barclays-downgrades-exact-sciences-to-equal-weight-raises-price-target-to-105

Barclays analyst Luke Sergott downgrades Exact Sciences (NASDAQ:EXAS) from Overweight to Equal-Weight and raises the price t...

 tech-stocks-fall-despite-nvidias-beat-walmart-jumps-6-whats-moving-markets-thursday

Nvidia Corp. (NASDAQ:NVDA) delivered another blockbuster quarter and raised its outlook, but even that wasn't enough to lif...

 abbotts-21-billion-exact-sciences-buyout-reshapes-cancer-diagnostics

Abbott will acquire Exact Sciences for $21 billion, adding Cologuard and expanding its diagnostics portfolio as analysts highli...

Core News & Articles

Abbott (NYSE:ABT) and Exact Sciences (NASDAQ:EXAS) today announced a definitive agreement for Abbott to acquire Exact Sciences,...

Core News & Articles

https://www.bloomberg.com/news/articles/2025-11-19/abbott-weighs-takeover-of-cancer-test-maker-exact-sciences

 piper-sandler-maintains-overweight-on-exact-sciences-raises-price-target-to-80

Piper Sandler analyst David Westenberg maintains Exact Sciences (NASDAQ:EXAS) with a Overweight and raises the price target ...

 exact-sciences-releases--validation-results-from-its-altus-study-showing-that-the-oncoguard-liver-blood-test-provides-superior-early-stage-and-overall-sensitivity-for-detecting-hepatocellular-carcinoma-compared-to-the-current-standard-of-care

Oncoguard® Liver blood test delivers seven times greater sensitivity for very early-stage hepatocellular carcinoma (HCC) versus...

 wells-fargo-maintains-overweight-on-exact-sciences-raises-price-target-to-85

Wells Fargo analyst Brandon Couillard maintains Exact Sciences (NASDAQ:EXAS) with a Overweight and raises the price target f...

 td-cowen-maintains-buy-on-exact-sciences-raises-price-target-to-90

TD Cowen analyst Dan Brennan maintains Exact Sciences (NASDAQ:EXAS) with a Buy and raises the price target from $74 to $90.

 td-cowen-maintains-buy-on-exact-sciences-raises-price-target-to-90

TD Cowen analyst Dan Brennan maintains Exact Sciences (NASDAQ:EXAS) with a Buy and raises the price target from $74 to $90.

 palantir-weighs-on-wall-street-bitcoin-slumps-5-whats-moving-markets-tuesday

Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION